Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Dec 2020 | From Akero Therapeutics

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases

Jul 2018 | FROM EXTERNAL EXPERTS

A systematic dissection of sequence elements determining β-Klotho and FGF interaction and signaling

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.